Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Assets Average (2018 - 2025)

Historic Assets Average for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to $111.9 million.

  • Innate Pharma's Assets Average fell 3633.24% to $111.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $111.9 million, marking a year-over-year decrease of 3633.24%. This contributed to the annual value of $153.6 million for FY2024, which is 2331.59% down from last year.
  • Latest data reveals that Innate Pharma reported Assets Average of $111.9 million as of Q2 2025, which was down 3633.24% from $140.9 million recorded in Q4 2024.
  • Innate Pharma's Assets Average's 5-year high stood at $343.6 million during Q2 2021, with a 5-year trough of $111.9 million in Q2 2025.
  • For the 5-year period, Innate Pharma's Assets Average averaged around $229.0 million, with its median value being $214.4 million (2023).
  • As far as peak fluctuations go, Innate Pharma's Assets Average tumbled by 9981.21% in 2021, and later plummeted by 1191.8% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Assets Average stood at $313.3 million in 2021, then dropped by 18.4% to $255.7 million in 2022, then dropped by 20.74% to $202.6 million in 2023, then tumbled by 30.46% to $140.9 million in 2024, then dropped by 20.56% to $111.9 million in 2025.
  • Its Assets Average stands at $111.9 million for Q2 2025, versus $140.9 million for Q4 2024 and $175.8 million for Q2 2024.